Boston Scientific Corp (BSX) - Total Assets
Based on the latest financial reports, Boston Scientific Corp (BSX) holds total assets worth $44.35 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Boston Scientific Corp - Total Assets Trend (1991–2025)
This chart illustrates how Boston Scientific Corp's total assets have evolved over time, based on quarterly financial data. Also see Boston Scientific Corp market cap and net worth for the company's overall valuation and market capitalisation.
Boston Scientific Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Boston Scientific Corp's total assets of $44.35 Billion consist of 20.1% current assets and 79.9% non-current assets. Review Boston Scientific Corp (BSX) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.97 Billion | 4.7% |
| Accounts Receivable | $2.93 Billion | 6.7% |
| Inventory | $2.94 Billion | 6.7% |
| Property, Plant & Equipment | $4.50 Billion | 10.3% |
| Intangible Assets | $7.02 Billion | 16.1% |
| Goodwill | $18.28 Billion | 41.9% |
Asset Composition Trend (1991–2025)
This chart illustrates how Boston Scientific Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Boston Scientific Corp (BSX) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Boston Scientific Corp's current assets represent 20.1% of total assets in 2025, a decrease from 64.9% in 1991.
- Cash Position: Cash and equivalents constituted 4.7% of total assets in 2025, up from 4.3% in 1991.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 57.0% of total assets, an increase from 7.0% in 1991.
- Asset Diversification: The largest asset category is goodwill at 41.9% of total assets.
Boston Scientific Corp Competitors by Total Assets
Key competitors of Boston Scientific Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Medacta Group SA
SW:MOVE
|
Switzerland | CHF860.76 Million |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
COPLAND ROAD CAPITAL NEW
F:A2P
|
Germany | €605.37 Million |
|
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298
|
China | CN¥7.51 Billion |
|
Shanghai Kinetic Medical Co
SHE:300326
|
China | CN¥3.38 Billion |
Boston Scientific Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.90 | 1.45 | 1.66 |
| Quick Ratio | 1.22 | 0.88 | 1.31 |
| Cash Ratio | 0.00 | 0.14 | 0.66 |
| Working Capital | $4.11 Billion | $2.28 Billion | $2.69 Billion |
Boston Scientific Corp - Advanced Valuation Insights
This section examines the relationship between Boston Scientific Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.79 |
| Latest Market Cap to Assets Ratio | 1.63 |
| Asset Growth Rate (YoY) | 10.9% |
| Total Assets | $43.67 Billion |
| Market Capitalization | $71.05 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Boston Scientific Corp's assets above their book value (1.63x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Boston Scientific Corp's assets grew by 10.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Boston Scientific Corp (1991–2025)
The table below shows the annual total assets of Boston Scientific Corp from 1991 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $43.67 Billion | +10.86% |
| 2024-12-31 | $39.40 Billion | +12.12% |
| 2023-12-31 | $35.14 Billion | +8.21% |
| 2022-12-31 | $32.47 Billion | +0.74% |
| 2021-12-31 | $32.23 Billion | +4.72% |
| 2020-12-31 | $30.78 Billion | +0.70% |
| 2019-12-31 | $30.57 Billion | +45.56% |
| 2018-12-31 | $21.00 Billion | +10.28% |
| 2017-12-31 | $19.04 Billion | +5.22% |
| 2016-12-31 | $18.10 Billion | -0.20% |
| 2015-12-31 | $18.13 Billion | +7.74% |
| 2014-12-31 | $16.83 Billion | +0.57% |
| 2013-12-31 | $16.73 Billion | -2.45% |
| 2012-12-31 | $17.15 Billion | -19.43% |
| 2011-12-31 | $21.29 Billion | -3.79% |
| 2010-12-31 | $22.13 Billion | -12.11% |
| 2009-12-31 | $25.18 Billion | -7.03% |
| 2008-12-31 | $27.08 Billion | -13.20% |
| 2007-12-31 | $31.20 Billion | +0.32% |
| 2006-12-31 | $31.10 Billion | +279.40% |
| 2005-12-31 | $8.20 Billion | +0.32% |
| 2004-12-31 | $8.17 Billion | +43.36% |
| 2003-12-31 | $5.70 Billion | +28.07% |
| 2002-12-31 | $4.45 Billion | +11.98% |
| 2001-12-31 | $3.97 Billion | +15.96% |
| 2000-12-31 | $3.43 Billion | -4.06% |
| 1999-12-31 | $3.57 Billion | -8.24% |
| 1998-12-31 | $3.89 Billion | +97.82% |
| 1997-12-31 | $1.97 Billion | +30.14% |
| 1996-12-31 | $1.51 Billion | +40.66% |
| 1995-12-31 | $1.07 Billion | +148.96% |
| 1994-12-31 | $431.80 Million | +33.60% |
| 1993-12-31 | $323.20 Million | +8.06% |
| 1992-12-31 | $299.10 Million | +117.69% |
| 1991-12-31 | $137.40 Million | -- |
About Boston Scientific Corp
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyG… Read more